NeuroSense Announces New Positive Data Analysis from PARADIG

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Phoenix , Arizona , United States , Italy , Canada , Israel , Jeremym Shefner , , Linkedin , Barrow Neurological Institute , Drug Administration , Neurosense Therapeutics Ltd , European Medicines Agency , Prnewswire Neurosense Therapeutics Ltd , European Network For The Cure , Nasdaq , Sense Therapeutics , Confidence Interval , European Network , Risk Factor , Seeing Primec , Rating Scale Revised , Investigator Initiated Trial , Orphan Drug Designation , European Medicines ,